Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for ASCVD

Roughly one in five people carries a cardiovascular risk factor they have never been tested for, that diet and exercise will not touch, and that is set almost entirely by genes inherited at birth. That risk factor is lipoprotein(a), and this AHA scientific statement is the document that made the case for taking it seriously.

Its argument is built on the strongest kind of evidence epidemiology can offer. Drawing together genetics, large population studies, and Mendelian randomization — the natural experiment of comparing people born with high versus low Lp(a) — the statement establishes that Lp(a) does not merely associate with cardiovascular disease but causes it. Because a person’s level is genetically determined and stable through life, a single measurement is enough to know it.

The statement also confronts the practical obstacles. It addresses the long-standing mess of measurement units (mg/dL versus nmol/L), pushes for standardized assays, and lays out how Lp(a) testing should fold into risk assessment — flagging the patient whose calculated risk looks reassuring but whose genes say otherwise.

The limitation, openly stated, was therapeutic. At publication there was no approved drug that lowered Lp(a) and proved it reduced events; the targeted agents were still in trials. Knowing the number could refine risk and intensify treatment of everything else, but could not yet treat the molecule directly.

We rate the evidence strong. This is a careful, authoritative synthesis that settled the causation question and turned Lp(a) from an academic curiosity into a test worth ordering — exactly the kind of inherited, invisible risk that the most efficient path to diagnosis is built to catch early.